Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
Earnings Data
Report Date
May 06, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.43Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented balanced, tangible progress on high-value clinical and regulatory fronts — notably CORDStrom's convincing RDEB data, manufacturing/CMC readiness, and INKmune Phase II success — and meaningful regulatory alignment for XPro's next-stage plan. However, these positives are tempered by a missed top-line primary endpoint for MINDFuL (leading to a $16.5M impairment), an increased net loss, a modest cash balance (~$24.8M) with runway only through Q1 2027, and the need for additional capital/partnerships and incremental CMC work for U.S. filings. Overall, the company has promising technical and regulatory momentum but faces near-term financial and execution risks that keep the picture balanced.Company Guidance
CORDStrom: Positive Clinical Efficacy and Safety in RDEB
Randomized placebo-controlled data showed clinically meaningful wound healing, reductions in itch, improvements in quality of life and a favorable safety profile for CORDStrom in RDEB; company expects to file a U.K. MAA by mid-summer 2026 and to submit EMA and U.S. (BLA) applications by end of 2026 with potential supply to patients in 2027.
CORDStrom: Manufacturing Consistency and Mechanism of Action
Demonstrated batch-to-batch manufacturing reproducibility from pooled donor MSC banks, established potency assays and elucidated a MOA (M1-to-M2 macrophage modulation and IL-10 induction) — key CMC and regulatory enablers for filings and commercialization.
XPro (Alzheimer's): Encouraging Signal and FDA Alignment for Phase III
MINDFuL data 'consistently favored' XPro across clinical, behavioral, patient-reported, blood and imaging biomarkers; company received End-of-Phase-II meeting minutes from FDA and aligned on an adaptive Phase III design (Phase IIb decision at 9 months, registrational 18-month primary endpoint using CDR-SB).
INKmune: Phase II Success in mCRPC
Completed Phase II in metastatic castration-resistant prostate cancer ahead of schedule and under budget; the study met its primary endpoint and 2 of 3 secondary endpoints, supporting further development/BD opportunities.
Reduced R&D Spend in 2025
Research and development expenses decreased to $20.7M in 2025 from $33.2M in 2024, a reduction of approximately 37.7%, primarily due to lower Alzheimer's trial expenses — improving near-term capital efficiency.
Near-term Financing Achieved
Raised net proceeds of approximately $27.5M during 2025 through a $17.4M registered direct offering (3.0M shares) and ~$10.1M from at-the-market sales (~1.3M shares), extending runway toward planned milestones.
INMB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INMB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | $1.14 | $1.13 | -0.88% |
Oct 30, 2025 | $1.73 | $1.83 | +5.78% |
Aug 07, 2025 | $2.79 | $2.56 | -8.24% |
May 08, 2025 | $7.09 | $6.97 | -1.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inmune Bio (INMB) report earnings?
Inmune Bio (INMB) is schdueled to report earning on May 06, 2026, TBA (Confirmed).
What is Inmune Bio (INMB) earnings time?
Inmune Bio (INMB) earnings time is at May 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INMB EPS forecast?
Currently, no data Available